Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 2/20 | 0.33 |
| ▸ | MC3R | P41968 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802739 | 0.91 | CCR1 (0.38) | CCKBRCCR1ALDH1A1MC4RMC3R | |
| SCHEMBL4457998 | 0.90 | CCKBR (0.41) | CCKBRALDH1A1CTSS | |
| SCHEMBL6798893 | 0.83 | CHRNA1 (0.42) | CCR1CTSSSIGMAR1 | |
| SCHEMBL6802732 | 0.83 | CCKBR (0.37) | CCKBRCCR1ALDH1A1 | |
| SCHEMBL6804307 | 0.77 | KMT2A (0.49) | CTSS | |
| SCHEMBL6808313 | 0.77 | CTSS (0.53) | CCKBRCCR1ALDH1A1CTSSSIGMAR1 | |
| SCHEMBL6797542 | 0.75 | CTSS (0.49) | CCKBRCCR1ALDH1A1CTSSCNR2 | |
| SCHEMBL6799404 | 0.70 | CTSL (0.62) | CTSS | |
| SCHEMBL6798370 | 0.69 | GPR132 (0.42) | ALDH1A1LMNA | |
| SCHEMBL6798801 | 0.69 | ACE (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| EP-1362052-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002057270-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CCKBR 3442/4885CCR1 1021/4885ALDH1A1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.